Ad
related to: fda indications for modafinil 5"This free app will find the best local deals." - AOL.com
Search results
Results from the WOW.Com Content Network
Modafinil performs moderately (but better than armodafinil or solriamfetol) [30] as a drug to overcome excessive daytime sleepiness caused by obstructive sleep apnea, [31] though it is recommended that people with apnea use continuous positive airway pressure (CPAP) therapy, that is a sleep breathing apparatus to prevent apnea, before starting ...
The drug or other substance has a currently accepted medical use in treatment in the United States. Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule III. The complete list of Schedule IV substances is as follows.
[1] [4] [5] Both enantiomers of modafinil are active as DRIs and wakefulness-promoting agents, but armodafinil is more potent and longer-acting. [ 4 ] [ 5 ] Armodafinil is produced by the pharmaceutical company Cephalon [ 12 ] and was approved by the United States Food and Drug Administration (FDA) in 2007.
For premium support please call: 800-290-4726 more ways to reach us
Eugeroics, in the sense of modafinil-type wakefulness promoting agents, include modafinil itself, armodafinil, and adrafinil, among others. [9] They are medically indicated for the treatment of certain sleep disorders , including excessive daytime sleepiness (EDS) in narcolepsy or obstructive sleep apnea (OSA).
Solriamfetol is used to promote wakefulness in the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea in adults. [1] It appears to be more effective in improving excessive daytime sleepiness associated with obstructive sleep apnea than certain other wakefulness-promoting agents including modafinil, armodafinil, and pitolisant.
Modafinil is a drug that helps keep people awake and alert (wakefulness-promoting agent or "eugeroic"). [ 1 ] [ 2 ] Most of the listed modafinil analogues are drugs that specifically target dopamine reuptake (reabsorption of a neurotransmitter by a neurotransmitter transporter ) with stronger effects ( selective DRIs with improved potency ...
"Indiana University Department of Medicine Clinical Pharmacology Drug Interactions Flockhart Table ™". "INHIBITORS, INDUCERS AND SUBSTRATES OF CYTOCHROME P450 ISOZYMES". "The Life Raft Group: Long List of Inhibitors and Inducers of CYP3A4 and CYP2D6". "DRUGBANK Online: Cytochrome P-450 Enzyme Inhibitors".